{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:53:14Z","timestamp":1761061994447,"version":"3.40.5"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejim.2024.07.004","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T13:34:42Z","timestamp":1722000882000},"page":"41-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Up and down in gastrointestinal cancer and bleeding with direct oral anticoagulants"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-8249","authenticated-orcid":false,"given":"Andr\u00e9s J.","family":"Mu\u00f1oz Mart\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8859-5881","authenticated-orcid":false,"given":"Javier","family":"Soto Alsar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Ortega Mor\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejim.2024.07.004_bib0001","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"H Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ejim.2024.07.004_bib0002","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejim.2024.07.004_bib0003","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejim.2024.07.004_bib0004","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1055\/s-0040-1720975","article-title":"Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the caravaggio study","volume":"121","author":"Ageno","year":"2021","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.ejim.2024.07.004_bib0005","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1055\/s-0041-1735194","article-title":"Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer","volume":"122","author":"Agnelli","year":"2022","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ejim.2024.07.004_bib0006","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"16","key":"10.1016\/j.ejim.2024.07.004_bib0007","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejim.2024.07.004_bib0008","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejim.2024.07.004_bib0009","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2024.07.004_bib0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejim.2024.04.012","article-title":"Direct oral anticoagulant-associated bleeding complications in patients with gastrointestinal cancer and venous thromboembolism","volume":"127C","author":"Nishimoto","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"4","key":"10.1016\/j.ejim.2024.07.004_bib0011","doi-asserted-by":"crossref","first-page":"e12736","DOI":"10.1002\/rth2.12736","article-title":"Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: the RIETECAT study","volume":"6","author":"Trujillo-Santos","year":"2022","journal-title":"Res Pract Thromb Haemost"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524002863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524002863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T22:13:40Z","timestamp":1726352020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524002863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":11,"alternative-id":["S0953620524002863"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.07.004","relation":{},"ISSN":["0953-6205"],"issn-type":[{"type":"print","value":"0953-6205"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Up and down in gastrointestinal cancer and bleeding with direct oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.04.012","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}